Her2-positive breast cancer Trials in New York, United States
Conditions / Her2-positive breast cancer / New York, United States
Research into Her2-positive breast cancer spans multiple therapeutic approaches and trial phases.
25 total trials for this combination
Showing top 10 of 25 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02213744 | MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients | TERMINATED | PHASE2/PHASE3 |
| NCT04893109 | ATEMPT 2.0: Adjuvant T-DM1 vs TH | RECRUITING | — |
| NCT05036252 | Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity | ACTIVE_NOT_RECRUITING | — |
| NCT00817362 | Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer | TERMINATED | PHASE2 |
| NCT01042379 | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | RECRUITING | PHASE2 |
| NCT04585750 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | RECRUITING | PHASE1/PHASE2 |
| NCT04569747 | A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer | RECRUITING | PHASE2 |
| NCT05705401 | Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT05705401 | Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT04893109 | ATEMPT 2.0: Adjuvant T-DM1 vs TH | RECRUITING | — |